![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, August 24, 2019 11:30:26 PM
"Currently there are no Kevetrin data (that I know of) for pancreatic cancer."
The reports below outlines the data which lead to Kevetrin's Orphan drug approval.
"In vivo efficacy of Kevetrin in the pancreatic MIA PaCa-2 xenograft model showed that tumor volumes were significantly reduced by 82% during 3 weeks of dosing at 200mg/kg. In a separate experiment when Kevetrin alone was dosed at 150mg/kg the tumor volume was reduced by 54%. The combination of Kevetrin and irinotecan further reduced tumor volumes by 88% showing synergistic activity.
https://www.biospace.com/article/releases/cellceutix-releases-data-used-in-receiving-fda-orphan-drug-designation-of-kevetrin-for-pancreatic-cancer-/
http://www.ipharminc.com/press-release/2016/11/17/cellceutixs-kevetrin-slows-pancreatic-cancer-tumor-growth-by-94-protocol-towards-clinical-trial-nearing
IPIX has postponed FDA trials while it awaits development of an oral form of Kevetrin.
https://www.pm360online.com/cellceutix-reports-advances-in-developing-kevetrin-as-an-oral-ovarian-cancer-treatment-company-seeks-to-develop-worlds-first-p53-modulating-oral-cancer-drug/
A patient with Pancreatic cancer was treated in the stage 1 trial:
"A Phase 1 clinical study was conducted with Kevetrin administered once weekly for 3 weeks with an off-week between cycles. Only one patient with pancreatic cancer was enrolled in the trial. The patient, who was diagnosed with pancreatic cancer received four full cycles of Kevetrin. Tumor measurements showed stable disease for more than three months."
https://www.biospace.com/article/releases/cellceutix-releases-data-used-in-receiving-fda-orphan-drug-designation-of-kevetrin-for-pancreatic-cancer-/
IMO it is doubtful an institution,clinic or oncologist would assume the responsibility of recommending Kevetrin, at its current stage of development, for a Supreme Court Justice with terminal Pancreatic Cancer.
GLTA Farrell
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM